New treatment strategies for hepatitis c infection
Yükleniyor...
Dosyalar
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Baishideng Publishing Group Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Hepatitis C infection can lead to cirrhosis and hepatocellular carcinoma and it is an important cause of mortality and morbidity. Achieving a sustained virological response has been the major aim for decades. Interferon treatment was the primarily developed therapy against the infection. Addition of the guanosine analog ribavirin to stop viral RNA synthesis increased the response rates as well as the adverse effects of the treatment. The increasing demands for alternative regimens led to the development of direct-acting antivirals (DAAs). The approval of sofosbuvir and simeprevir signaled a new era of antiviral treatment for hepatitis C infection. Although the majority of studies have been performed with DAAs in combination with interferon and resulted in a decrease in treatment duration and increase in response rates, the response rates achieved with interferon-free regimens provided hope for patients ineligible for therapy with interferon. Most DAA studies are in phase. leading to phase.. In the near future more DAAs are expected to be approved. The main disadvantage of the therapy remains the cost of the drugs. Here, we focus on new treatment strategies for hepatitis C infection as well as agents targeting hepatitis C virus replication that are in clinical development.
Açıklama
WOS: 000439204000006
PubMed: 26301052
PubMed: 26301052
Anahtar Kelimeler
Direct-acting antivirals, Eradication, Genotype, Hepatitis C virus infection, Interferon-free, Treatment
Kaynak
World Journal Of Hepatology
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
7
Sayı
17
